Patient and disease characteristics
| Characteristic . | Entire cohort (N = 115), n (%) or n/N (%) . | HDMTX subgroup (n = 52), n (%) or n/N (%) . |
|---|---|---|
| Patient characteristics | ||
| Age >60 y | 81 (70) | 29 (56) |
| Male sex | 68 (59) | 32 (62) |
| Performance status ≥2 | 89 (77) | 32 (62) |
| Elevated lactate dehydrogenase | 24/83 (29) | 14/51 (27) |
| Ocular involvement | 5 (4) | 5 (10) |
| Deep brain lesions | 67/111 (60) | 31/50 (62) |
| ≥2 brain lesions | 46/111 (41) | 24/50 (48) |
| Largest mass ≥4 cm | 61/109 (56) | 31 (60) |
| Extra-CNS disease | 0 (0) | 0 (0) |
| Frontline treatment | ||
| BSC | 23 (20) | |
| WBRT | 40 (35) | |
| HDMTX-based chemotherapy | 52 (45) | |
| HDMTX regimen | 41 (79) | |
| MIDVAP regimen | 11 (21) | |
| Rituximab | 11 (21) | |
| Radiation | 18 (35) | |
| Autologous SCT | 0 (0) | |
| IHC for cell of origin | ||
| CD10 positive | 4/110 (4) | 1/50 (2) |
| BCL6 positive | 85/108 (79) | 34/49 (69) |
| MUM1 positive* | 33/109 (30) | 14/50 (28) |
| FOXP1 positive | 84/111 (76) | 34/50 (68) |
| LMO2 positive | 34/106 (32) | 14/47 (30) |
| GCET1 positive | 5/114 (4) | 2/51 (4) |
| Cell of origin algorithms | ||
| Non-GCB (Hans algorithm) | 82/109 (75) | 38/50 (76) |
| Non-GCB (Choi algorithm) | 93/109 (85) | 41/50 (82) |
| Non-GCB (Tally algorithm) | 108/110 (98) | 50/50 (100) |
| IHC for other proteins | ||
| MYC positive | 37/93 (40) | 16/38 (42) |
| BCL2 positive | ||
| 124 antibody | 69/92 (75) | 31/39 (79) |
| E17 antibody | 87/111 (78) | 40/50 (80) |
| MYC + BCL2 positive | ||
| 124 antibody (BCL2) | 30/88 (35) | 13/37 (35) |
| E17 antibody (BCL2) | 32/92 (35) | 13/38 (34) |
| PD-L1 positive | 31/107 (29) | 13/46 (28) |
| HLA-DP positive | ||
| Cytoplasmic staining only | 53/112 (47) | 28/51 (55) |
| Membranous staining† | 25/112 (22) | 8/51 (16) |
| EBER positive | 1/108 (1) | 0 (0) |
| Characteristic . | Entire cohort (N = 115), n (%) or n/N (%) . | HDMTX subgroup (n = 52), n (%) or n/N (%) . |
|---|---|---|
| Patient characteristics | ||
| Age >60 y | 81 (70) | 29 (56) |
| Male sex | 68 (59) | 32 (62) |
| Performance status ≥2 | 89 (77) | 32 (62) |
| Elevated lactate dehydrogenase | 24/83 (29) | 14/51 (27) |
| Ocular involvement | 5 (4) | 5 (10) |
| Deep brain lesions | 67/111 (60) | 31/50 (62) |
| ≥2 brain lesions | 46/111 (41) | 24/50 (48) |
| Largest mass ≥4 cm | 61/109 (56) | 31 (60) |
| Extra-CNS disease | 0 (0) | 0 (0) |
| Frontline treatment | ||
| BSC | 23 (20) | |
| WBRT | 40 (35) | |
| HDMTX-based chemotherapy | 52 (45) | |
| HDMTX regimen | 41 (79) | |
| MIDVAP regimen | 11 (21) | |
| Rituximab | 11 (21) | |
| Radiation | 18 (35) | |
| Autologous SCT | 0 (0) | |
| IHC for cell of origin | ||
| CD10 positive | 4/110 (4) | 1/50 (2) |
| BCL6 positive | 85/108 (79) | 34/49 (69) |
| MUM1 positive* | 33/109 (30) | 14/50 (28) |
| FOXP1 positive | 84/111 (76) | 34/50 (68) |
| LMO2 positive | 34/106 (32) | 14/47 (30) |
| GCET1 positive | 5/114 (4) | 2/51 (4) |
| Cell of origin algorithms | ||
| Non-GCB (Hans algorithm) | 82/109 (75) | 38/50 (76) |
| Non-GCB (Choi algorithm) | 93/109 (85) | 41/50 (82) |
| Non-GCB (Tally algorithm) | 108/110 (98) | 50/50 (100) |
| IHC for other proteins | ||
| MYC positive | 37/93 (40) | 16/38 (42) |
| BCL2 positive | ||
| 124 antibody | 69/92 (75) | 31/39 (79) |
| E17 antibody | 87/111 (78) | 40/50 (80) |
| MYC + BCL2 positive | ||
| 124 antibody (BCL2) | 30/88 (35) | 13/37 (35) |
| E17 antibody (BCL2) | 32/92 (35) | 13/38 (34) |
| PD-L1 positive | 31/107 (29) | 13/46 (28) |
| HLA-DP positive | ||
| Cytoplasmic staining only | 53/112 (47) | 28/51 (55) |
| Membranous staining† | 25/112 (22) | 8/51 (16) |
| EBER positive | 1/108 (1) | 0 (0) |